Abstract
The tumor necrosis factor (TNF) gene is an immediate early gene, rapidly transcribed in a variety of cell types following exposure to a broad range of pathogens and signals of inflammation and stress. Regulation of TNF gene expression at the transcriptional level is cell type- and stimulus-specific, involving epigenetic mechanisms or miRNAs. A better knowledge of the molecular mechanisms that control TNF gene regulation and TNF signalling will provide deeper understanding of the initiation and development of apoptotic and inflammatory processes triggered by TNF cytokine in the gut. The described efforts to embed TNF in clinical treatment regiments reflect its attractive effectiveness in killing tumor cells. Whether the described strategies will achieve the success of incorporating TNF in lower gastrointestinal tract therapy for inflammatory diseases and cancer remains to be determined.
Keywords: TNF signalling, apoptosis, colorectal tumor cells, radiotherapy, intestinal epithelial cells, immune cells, tumor necrosis factor (TNF), cancer, Apoptosis, cytotoxic therapy
Current Pharmaceutical Biotechnology
Title:Apoptosis Signalling Activated by TNF in the Lower Gastrointestinal Tract-Review
Volume: 13 Issue: 11
Author(s): Natalya Benderska, Saritha Chakilam, Manuela Hugle, Jelena Ivanovska, Muktheshwar Gandesiri, Jan Schulze-Luhrmann, Khuloud Bajbouj, Ronald Croner and Regine Schneider-Stock
Affiliation:
Keywords: TNF signalling, apoptosis, colorectal tumor cells, radiotherapy, intestinal epithelial cells, immune cells, tumor necrosis factor (TNF), cancer, Apoptosis, cytotoxic therapy
Abstract: The tumor necrosis factor (TNF) gene is an immediate early gene, rapidly transcribed in a variety of cell types following exposure to a broad range of pathogens and signals of inflammation and stress. Regulation of TNF gene expression at the transcriptional level is cell type- and stimulus-specific, involving epigenetic mechanisms or miRNAs. A better knowledge of the molecular mechanisms that control TNF gene regulation and TNF signalling will provide deeper understanding of the initiation and development of apoptotic and inflammatory processes triggered by TNF cytokine in the gut. The described efforts to embed TNF in clinical treatment regiments reflect its attractive effectiveness in killing tumor cells. Whether the described strategies will achieve the success of incorporating TNF in lower gastrointestinal tract therapy for inflammatory diseases and cancer remains to be determined.
Export Options
About this article
Cite this article as:
Benderska Natalya, Chakilam Saritha, Hugle Manuela, Ivanovska Jelena, Gandesiri Muktheshwar, Schulze-Luhrmann Jan, Bajbouj Khuloud, Croner Ronald and Schneider-Stock Regine, Apoptosis Signalling Activated by TNF in the Lower Gastrointestinal Tract-Review, Current Pharmaceutical Biotechnology 2012; 13(11) . https://dx.doi.org/10.2174/138920112802501971
DOI https://dx.doi.org/10.2174/138920112802501971 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
Current Drug Targets Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells
Current Medicinal Chemistry Linkage of Stress with Neuromuscular Disorders
CNS & Neurological Disorders - Drug Targets Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Peptide-Mediated Delivery of Therapeutic and Imaging Agents Into Mammalian Cells
Current Pharmaceutical Design Some Personal Memories of Bob Chanock
Infectious Disorders - Drug Targets Neural Differentiation and Therapeutic Potential of Adipose Tissue Derived Stem Cells
Current Stem Cell Research & Therapy Tumor Necrosis Factor: Renaissance as a Cancer Therapeutic?
Current Cancer Drug Targets System Models, Assays and Endpoint Parameters to Evaluate Anticancer Compounds During Preclinical Screening
Current Medicinal Chemistry Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Current Drug Delivery Contemporary Animal Models For Human Gene Therapy Applications
Current Gene Therapy Thrombospondin and Apoptosis: Molecular Mechanisms and Use for Design of Complementation Treatments
Current Drug Targets Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine Role of the RAS in Pancreatic Cancer
Current Cancer Drug Targets Interfering with Hedgehog Pathway: New Avenues for Targeted Therapy in Rhabdomyosarcoma
Current Drug Targets New Therapeutic Property of Dimebon as a Neuroprotective Agent
Current Medicinal Chemistry Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials The Effect of Lycopene on the PI3K/Akt Signalling Pathway in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Study of Splicing Factor, Proline- and Glutamine-rich by Proteomic Techniques in Human Malignant and Nonmalignant Cell Lines
Protein & Peptide Letters